Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

WRN inhibitor GSK4418959

An orally bioavailable inhibitor of the Werner syndrome ATP-dependent helicase (WRN), with potential antineoplastic activity. Upon oral administration, WRN inhibitor GSK4418959 targets, binds to and inhibits the activity of WRN. This may inhibit the growth of susceptible tumor cells, such as ones with high microsatellite instability (MSI-H). WRN, a multifunctional enzyme with both helicase and exonuclease activities, plays a key role in DNA replication and repair. It is overexpressed in a variety of cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Werner syndrome ATP-dependent helicase inhibitor GSK4418959 WRNi GSK4418959
Code name:	GSK 4418959 GSK-4418959 GSK4418959

WRN inhibitor GSK4418959

Search NCI's Drug Dictionary